Evidence map›Paper›PMID 41136921›Full record

SynthesisBMC gastroenterology2025

Efficacy of TDF, TAF, TMF, and TDF-to-TAF switch in chronic hepatitis B: a network meta-analysis.

Shuqi Yang, Yijie Lin, Huatang Zhang, Yanlan Liang, Wenjin Yuan, Xing Wang, Wenwu Lin, Wencong Hong, Zhijun Su, Dawu Zeng and 1 more

Abstract readNetwork Meta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuqi Yang *Department of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China.
Yijie Lin *Department of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China.
Huatang ZhangDepartment of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China.
Yanlan LiangDepartment of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China.
Wenjin YuanDepartment of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China.
Xing WangDepartment of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China.
Wenwu LinDepartment of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China.
Wencong HongDepartment of Respiratory and Critical Care Medicine, Nan 'an Hospital, Fujian, 362000, Quanzhou, China.
Zhijun SuDepartment of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China. su2366@sina.com.
Dawu ZengDepartment of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Clinical Research Center for Hepatopathy and Intestinal Diseases of Fujian Province, Fujian Medical University, Fujian, 350000, Fuzhou, China. zengdw1980@fjmu.edu.cn.
Xueping YuDepartment of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian province, Fujian Medical University Affiliated First Quanzhou hospital, No. 250 East Street, Licheng District, Fujian, 362000, Quanzhou, China. xpyu15@fudan.edu.cn.

Funding

Major Science and Technology innovation Project of Fujian Province 2023Y9269National Natural Science Foundation of China 82370604Natural Science Foundation of Fujian Province 2023J01239
6 · The paper itself

Abstract

objectiveWe compared the efficacy of four treatment strategies for chronic hepatitis B (CHB): tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), tenofovir amibufenamide (TMF), and TDF-to-TAF switch strategies strategy. We conducted a network meta-analysis to provide evidence-based clinical guidance.

methodsWe systematically retrieved PubMed, Web of Science, Cochrane Library, Embase, and China National Knowledge Infrastructure (CNKI) databases up to April 2025 for randomized controlled trials (RCTs) and cohort studies. We assessed literature quality using the Cochrane Risk of Bias (ROB) tool and Newcastle-Ottawa Scale (NOS). Stata 17 was employed for network meta-analysis, focusing on virological response rate, hepatitis B surface antigen (HBsAg) clearance rate, hepatitis B e antigen (HBeAg) clearance rate, and alanine aminotransferase (ALT) normalization rate.

resultsVirological response did not differ between TMF monotherapy and TDF-to-TAF switch (OR = -0.03; 95% CI -0.42 to 0.36). HBsAg clearance was similar between TAF and TMF (95% CI: -1.17-1.14). For the rate of HBeAg loss, both TAF and TMF exhibited favorable therapeutic effects. For ALT normalization rate, TMF monotherapy was the most effective, with an average effect size of 0.11 (95% CI: -0.14-0.37), while TDF monotherapy was generally inferior to the other three treatment strategies.

conclusionOur findings may help guide the selection of individualized CHB treatment strategies. However, given the limited evidence and potential bias, these results are preliminary and must be interpreted with caution. For regimens such as TMF that lack robust data, well-established alternatives should be preferred. Long-term, multi-endpoint studies are required to confirm both efficacy and safety before routine clinical adoption.

Indexed as

AdenineAntiviral AgentsHepatitis B, ChronicTenofovirAlanineAlanine TransaminaseDrug SubstitutionHepatitis B e AntigensHepatitis B Surface AntigensHumansTreatment OutcomeAdenineAlanineAlanine TransaminaseAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensTenofovirtenofovir alafenamideKeywords: chronic hepatitis bNetwork meta-analysisTAFTDFTDF-to-TAF switchTMF

Identifiers

PMID41136921
PMCPMC12553160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.